Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00161473 · ClinicalTrials.gov registry record · NA

Alzheimer's in Long-Term Care--Treatment for Agitation

A NA study, sponsored by University of Washington.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT00161473: Completed NA study, sponsored by University of Washington.

NCT00161473 is a NA study that has completed, run by University of Washington. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00161473, a NA study, has completed, sponsored by University of Washington.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.

Primary Outcome

The Clinical Global Impression of Change (CGIC) is a 7 point scale, where 1 indicates "markedly improved," 4 indicates "no change," and 7 indicates "markedly worse."

Interventions

  • DRUG prazosin
  • DRUG placebo (inert substance)

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2001-01
Est. Completion 2009-09
Phase NA
University of Washington

1,048 total trials

What the finished NCT00161473 record still lists

NCT00161473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which prazosin is the first listed.

NCT00161473 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00161473 about?

NCT00161473 is a clinical study titled "Alzheimer's in Long-Term Care--Treatment for Agitation". The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.

What is the current status of trial NCT00161473?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2001-01. Estimated completion is 2009-09.

What interventions are being tested in trial NCT00161473?

The interventions under investigation include: prazosin (DRUG), placebo (inert substance) (DRUG).

Who is sponsoring clinical trial NCT00161473?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00161473's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00161473, the US trial registry maintained by the National Library of Medicine. NCT00161473 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.